The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

ADC Contract Manufacturing Market (3rd Edition), 2018-2030

  • Lowest Price Guaranteed From USD 3,499

  • Published
    September 2018

  • Pages
    385

  • View Count
    3383

Example Insights

   

 

Overview

Antibody drug conjugates (ADCs) are one of the most popular classes of targeted therapeutic agents and have captured the attention of both large and small pharmaceutical companies, and academic / research institutions across the world. Fundamentally, these complex biotherapeutic entities represent the combination of the target specificity of an antibody and the cytotoxic potential of a chemotherapy drug; such conjugates are believed to be more efficient and effective in specifically identifying and eliminating cells / pathogens that are associated with disease(s). Since the approval of first ADC (MYLOTARG™) in 2000and its subsequent withdrawal in the year 2010, the ADC market has evolved considerably. Presently, there are four approved ADCs in the market: BESPONSA (2017), MYLOTARG™ (2017, reapproval), KADCYLA (2013) and ADCETRIS (2011). In fact, in the last 4-5 years, the market has witnessed an increasing interest from drug developers and healthcare investors alike. This is justified by the fact that currently there are close to 200 unique ADC product candidates in the clinical / preclinical phase of development.

Owing to the fact that these novel conjugates are highly potent toxic molecules, their manufacturing requires elaborate technical capabilities, along with the required expertise and manufacturing acumen related to both biologics and highly potent chemical substances. Specifically, the development of an antibody requires experience in protein engineering, cell line development, bioprocess development and related scale-up techniques. The production of the cytotoxic payloads that are used in ADCs requires specialized manufacturing facilities and equipment, highly contained production environments and experts in advanced synthetic chemistry and purification techniques. In addition, ADC developers require access to state-of-art linker technologies and must possess the ability to carry out the bioconjugation of the antibody to the cytotoxic drug. Due to the aforementioned challenges, stakeholders generally don’t opt for manufacturing ADCs in-house. In fact, some of the leading players in this domain are dependent on contract manufacturers for the supply of one or more components of their ADC product candidates. Although some big pharma companies carry out in-house manufacturing of their ADC products, the trend of outsourcing such operations is likely to flourish in the coming years. This trend is expected to be driven by the several small companies and start-ups that are presently involved in development of ADCs.

 

Scope of the Report

The “ADC Contract Manufacturing Market (3rd edition), 2018-2030” report offers a comprehensive study of the current scenario and future potential of the contract manufacturing market for ADCs. The study features an in-depth analysis, highlighting the capabilities of contract services providers engaged in this domain. In addition to other elements, the study includes:

  • An overview of the current status of the market with respect to the players involved in the manufacturing of ADCs. It features information on headquarters, size of the company, the types of services offered (antibody manufacturing / HPAPI or cytotoxic manufacturing / linker manufacturing / conjugation / fill-finish), location of manufacturing facilities, year of establishment of company / organization, scale of operations, and additional development services offered for ADCs (proof-of-concept studies / process development and scale-up / anaytical development).
  • Elaborate profiles of the contract service providers that are either one-stop-shops (offering services from antibody manufacturing to fill/ finish operations) or offer conjugation services at the commercial scale. Each profile provides a brief overview of the company, its financial information, details on ADC manufacturing capabilities, location of facilities, recent developments, and a comprehensive future outlook.
  • A comparative analysis of the key contract manufacturers based onvarious parameters, including company size, year of establishment, number of ADC manufacturing services offered, annual revenues, scale of operation, number of ADC development services offered and number of facilities for conjugation services.
  • An analysis of the recent investments (since 2012) made in this domain, the proceeds of which were intended to be used for the expansion or establishment of new facilities dedicated to offering ADC related services.
  • An analysis of the recent collaborations (since 2012) focused on manufacturing of ADCs on the basis of year in which the agreement was signed, type of agreement, key players and the geographical distribution of this activity.
  • An estimate of the overall ADC manufacturing / bioconjugation capacity (in grams / batch) of contract service providers based on information provided on their respective websites (wherever available) and additional data collated via secondary and primary research. The analysis highlights the distribution of global capacity by size of the company / organization (small-sized, mid-sized and large-sized) and geography (North America, Europe and Asia Pacific).
  • An overview of the ADCs that are already approved and those that are under development (clinical and preclinical), featuring information related to their current phase of development (wherever applicable), key target indications, developer company / organization, affiliated technology provider(s) and the type(s) of cytotoxin(s) and linker(s) used.
  • A review of the evolution of ADC conjugation technologies, highlighting the various types pf approaches that have been adopted in the past, and the different generations of linkers. It also highlights the competition between contemporary technology platforms.
  • A comprehensive geographical clinical trial analysis of completed, ongoing and planned studies of various ADCs (approved / under development). It provides details related to the different types of payloads and linkers investigated / being investigated across various geographies, based on the number of trials registered, current trial status, phase of development, number of patients enrolled and duration of the (recently initiated) trials (2015 onwards).
  • An informed estimate of the annual demand for ADC products (in grams), taking into account commercial, as well as clinical scale requirements, based on parameters such as target patient population, dosing frequency and dose strength of approved products and clinical stage candidates.
  • A discussion on affiliated trends, key drivers and challenges, under a SWOT framework, featuring a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on the overall ADC contract manufacturing market.

One of the key objectives of this report was to evaluate the current opportunity and the future potential of the ADC contract manufacturing market over the coming decade. We have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2018-2030. In addition, we have provided the likely distribution of the market based on scale of operation (commercial, phase III, phase II and phase I), component / process type (antibody manufacturing, HPAPI / cytotoxic production, conjugation / linker and fill / finish), target indications (solid tumors and hematological malignancies), type of payload used (auristatin, calicheamicin (ozogamicin), duocarmycin, DXd (exatecan derivative), maytansinoid, pyrrolobenzodiazepines (talirine, tesirine) and others), type of linker used (succinimidyl 4-(n-maleimidomethyl) cyclohexane-1-carboxylate, valine-citrulline, hydrazone, valine-alanine, n-succinimidyl-4-(2-pyridyldithio) butanoate and others) and geography (North America, Europe, Asia Pacific and rest of the world).

The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. Our opinions and insights presented in this study were influenced by discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with following stakeholders:

  • Aldo Braca (Chief Executive Officer, BSP Pharmaceuticals) and Giorgio Salciarini (Technical Business Development Manager, BSP Pharmaceuticals)
  • Anthony DeBoer (Director, Business Development, Synaffix)
  • Christian Bailly (Director of CDMO, Pierre Fabre)
  • Christian Rohlff (Chief Executive Officer & Founder, Oxford BioTherapeutics)
  • Jennifer L. Mitcham (Director,  Business Development, Catalent Pharma Solutions) and Stacy McDonald (Group Product Manager, Catalent Pharma Solutions)
  • John Burt (Chief Executive Officer, Abzena)
  • Laurent Ducry (Head of Bioconjugates Commercial Development, Lonza)
  • Mark Wright (Site Head, Piramal Healthcare)
  • Sasha Koniev (Chief Executive Officer & Co-Founder, Syndivia)
  • Anonymous (Director, Business Development, Leading CMO)
  • Anonymous (Chief Executive Officer, Leading CMO)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter 2  provides an executive summary of the insights captured during our research. It offers a high level view on the likely evolution of the ADC contract manufacturing marketin the mid to long term.

Chapter 3  is a general introduction to ADCs and the manufacturing requirements of such therapeutic products. It includes a detailed discussion on the structure of an ADC and its various components, manufacturing steps and associated challenges. The chapter also provides an overview of the growing trend of contract manufacturing, along with the challenges associated with supply chain and the growing demand for one-stop-shops. Further, it features a discussion on the various parameters that a sponsor company needs to consider while selecting a contract manufacturing partner.

Chapter 4  provides a comprehensive overview of contract manufacturers that are actively involved in the production or conjugation of ADCs. The chapter features information on headquarters, size of the company, types of services offered (antibody manufacturing / HPAPI or cytotoxic manufacturing / linker manufacturing / conjugation / fill-finish), location of manufacturing facilities, year of establishment of company / organization, scale of operation, and additional development services offered for ADCs (proof-of-concept studies / process development and scale-up / analytical development). The chapter also includes a list of various contract manufacturers offering antibody production services along with the information on the location of their headquarters. Further, it provides a list of HPAPI / cytotoxic drug manufacturers along with the information on location of facilities dedicated to the manufacturing of such components.

Chapter 5  features profiles of contract service providers that are either one-stop-shops (offering services from antibody manufacturing to fill/ finish operations) or offer conjugation services at the commercial scale. Each profile provides a brief overview of the company, its financial information, details on ADC manufacturing capabilities, location of facilities, recent developments, and a comprehensive future outlook.

Chapter 6  features a detailed comparative analysis of the ADC contract manufacturers. The companies were compared on the basis of various parameters including company size, year of establishment, number of ADC manufacturing services offered, annual revenues, scale of operation, number of ADC development services offered and number of facilities for conjugation services. The results of this analysis were used to highlight the features of the most competent companies working in this domain.

Chapter 7  highlightstheinvestments made by CMOs to expand or set up new facilities in order to support their ongoing operations. For each such instance, we have provided information on month / year of the development, type of development, amount invested ( if available ), focus area (manufacturing, analytical / development and fill / finish), scale of operation (preclinical, clinical and commercial) and location of the facility in which the investment was made.

Chapter 8  features an elaborate discussion and analysis of the various collaborations and partnerships that have been inked between different players in this market. We have also discussed the different partnership models (including research agreements, manufacturing agreements, technology licensing agreements, product development agreements and acquisitions / mergers) and the most common forms of deals / agreements that have been established between 2012-H1 2018. It consists of a schematic representation showcasing the players that have established the maximum number of alliances related to the manufacturing of ADCs. Furthermore, we have provided a world map representation of the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 9  features a comprehensive analysis of the overall installed manufacturing / bioconjugation capacity of contract service providers and an estimate of the quantity of ADCs that can be produced per batch. The analysis highlights the distribution of global capacity by size of the company / organization (small-sized, mid-sized and large-sized) and geography (North America, Europe and Asia Pacific).

Chapter 10  provides a comprehensive overview of the market landscape of ADCs that are already approved and those that are under development (clinical and preclinical). This chapter includes information related to their current phase of development (wherever applicable), key target indications, developer company / organization, affiliated technology provider(s) and the type(s) of cytotoxin(s) and linker(s) used.

Chapter 11  features an elaborate discussion and competitive analysis of the various ADC conjugation approaches. This chapter also features an overview of the evolution of these technologies, highlighting the competition between contemporary technology platforms.

Chapter 12  features a comprehensive geographical clinical trial analysis of completed, ongoing and planned studies of various ADCs (approved / under development). The analysis provides details related to the different types of payloads and linkers investigated / being investigated across various geographies, based on the number of trials registered, current trial status, phase of development, number of patients enrolled and duration of the (recently initiated) trials (2015 onwards).

Chapter 13  features acomprehensive analysis of the annual demand of ADCs (in grams) taking into account commercial, as well as clinical scale requirements. This was based on the parameters such as target patient population, dosing frequency and dose strength of approved products and clinical stage candidates.

Chapter 14  presents a comprehensive market forecast analysis, highlighting the likely growth of the contract manufacturing market of ADCs, till 2030. The chapter provides likely distribution of the projected future opportunity based on scale of operation (commercial, phase III, phase II and phase I), component / process type (antibody, cytotoxic / linker, conjugation, fill / finish and others), target indications (solid tumors and hematological malignancies), type of payload used (auristatin, calicheamicin (ozogamicin), duocarmycin, DXd (exatecan derivative), maytansinoid, pyrrolobenzodiazepines (talirine, tesirine) and others), type of linker used (succinimidyl 4-(n-maleimidomethyl) cyclohexane-1-carboxylate, valine-citrulline, hydrazone, valine-alanine, n-succinimidyl-4-(2-pyridyldithio) butanoate and others) and geography (North America, Europe, Asia Pacific and rest of the world).

Chapter 15  provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of ADC contract manufacturing market, under a comprehensive SWOT framework.

Chapter 16  is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 17  is a collection of interview transcripts of the discussions that were held with key stakeholders in this market. The chapter provides details of interviews held with  Aldo Braca (Chief Executive Officer, BSP Pharmaceuticals) and Giorgio Salciarini (Technical Business Development Manager, BSP Pharmaceuticals), Anthony DeBoer (Director, Business Development, Synaffix), Christian Bailly (Director of CDMO, Pierre Fabre), Christian Rohlff (Chief Executive Officer & Founder, Oxford BioTherapeutics), Jennifer L. Mitcham (Director,  Business Development, Catalent Pharma Solutions) and Stacy McDonald (Group Product Manager, Catalent Pharma Solutions), John Burt (Chief Executive Officer, Abzena), Laurent Ducry (Head of Bioconjugates Commercial Development, Lonza), Mark Wright (Site Head, Piramal Healthcare), Sasha Koniev (Chief Executive Officer & Co-Founder, Syndivia), Anonymous (Director, Business Development, Leading CMO) and Anonymous (Chief Executive Officer, Leading CMO)

Chapter 18  is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 19  is an appendix, which provides the list of companies and organizations mentioned in the report.

Table of Contents

 

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. INTRODUCTION
3.1. Chapter Overview
3.2. Essential Components of ADCs
3.2.1. Antibody
3.2.2. Cytotoxin
3.2.3. Linker
3.3. ADC Manufacturing
3.3.1. Key Steps
3.3.2. Technical Challenges
3.3.3. Growing Trend of Contract Manufacturing
3.4. Challenges Associated with Supply Chain and Method Transfer
3.4.1. Growing Demand for One Stop Shops and Integrated Service Providers
3.5. Selecting a CMO Partner
 
4. ADC CONTRACT MANUFACTURERS: CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. ADC Contract Manufacturers: Overall Market Landscape
4.2.1. Distribution by Location of Headquarters
4.2.2. Distribution by Year of Establishment
4.2.3. Distribution by Company Size
4.2.4. Distribution by Service(s) Offered
4.2.5. Distribution by Location of Manufacturing Facility
4.2.6. Distribution by Scale of Operation
4.2.7. Distribution by Other ADC Services Offered
4.3. Antibody Manufacturing Service Providers
4.4. HPAPI / Cytotoxic Drug Manufacturing Service Providers
 
5. COMPANY PROFILES
5.1. Chapter Overview
5.2. Abzena
5.2.1. Company Overview and Financial Information
5.2.2. ADC Offerings
5.2.3. Manufacturing Facilities
5.2.4. Recent Developments
5.2.5. Future Outlook
 
5.3. Ajinomoto Althea
5.3.1. Company Overview and Financial Information
5.3.2. ADC Offerings
5.3.3. Manufacturing Facilities
5.3.4. Recent Developments
5.3.5. Future Outlook
 
5.4. BSP Pharmaceuticals
5.4.1. Company Overview
5.4.2. ADC Offerings
5.4.3. Manufacturing Facilities
5.4.4. Recent Developments
5.4.5. Future Outlook
 
5.5. CARBOGEN AMCIS
5.5.1. Company Overview and Financial Information
5.5.2. ADC Offerings
5.5.3. Manufacturing Facilities
5.5.4. Recent Developments
5.5.5. Future Outlook
 
5.6. Catalent Pharma Solutions
5.6.1. Company Overview and Financial Information
5.6.2. ADC Offerings
5.6.3. Manufacturing Facilities
5.6.4. Recent Developments
5.6.5. Future Outlook
 
5.7. Cerbios-Pharma
5.7.1. Company Overview and Financial Information
5.7.2. ADC Offerings
5.7.3. Manufacturing Facilities
5.7.4. Recent Developments
5.7.5. Future Outlook
 
5.8. Creative Biolabs
5.8.1. Company Overview
5.8.2. ADC Offerings
5.8.3. Manufacturing Facilities
5.8.4. Recent Developments
5.8.5. Future Outlook
 
5.9. Goodwin Biotechnology
5.9.1. Company Overview
5.9.2. ADC Offerings
5.9.3. Manufacturing Facilities
5.9.4. Recent Developments
5.9.5. Future Outlook
 
5.10. Levena Biopharma
5.10.1. Company Overview
5.10.2. ADC Offerings
5.10.3. Manufacturing Facilities
5.10.4. Recent Developments
5.10.5. Future Outlook
 
5.11. Lonza
5.11.1. Company Overview and Financial Information
5.11.2. ADC Offerings
5.11.3. Manufacturing Facilities
5.11.4. Recent Developments
5.11.5. Future Outlook
 
5.12. MabPlex
5.12.1. Company Overview
5.12.2. ADC Offerings
5.12.3. Manufacturing Facilities
5.12.4. Recent Developments
5.12.5. Future Outlook
 
5.13. Merck (SAFC)
5.13.1. Company Overview and Financial Information
5.13.2. ADC Offerings
5.13.3. Manufacturing Facilities
5.13.4. Recent Developments
5.13.5. Future Outlook
 
5.14. Novasep
5.14.1. Company Overview and Financial Information
5.14.2. ADC Offerings
5.14.3. Manufacturing Facilities
5.14.4. Recent Developments
5.14.5. Future Outlook
 
5.15. Pierre Fabre
5.15.1. Company Overview and Financial Information
5.15.2. ADC Offerings
5.15.3. Manufacturing Facilities
5.15.4. Recent Developments
5.15.5. Future Outlook
 
5.16. Piramal Pharma Solutions
5.16.1. Company Overview and Financial Information
5.16.2. ADC Offerings
5.16.3. Manufacturing Facilities
5.16.4. Recent Developments
5.16.5. Future Outlook
 
5.17. Syngene
5.17.1. Company Overview and Financial Information
5.17.2. ADC Offerings
5.17.3. Manufacturing Facilities
5.17.4. Recent Developments
5.17.5. Future Outlook
 
5.18. WuXi Biologics
5.18.1. Company Overview and Financial Information
5.18.2. ADC Offerings
5.18.3. Manufacturing Facilities
5.18.4. Recent Developments
5.18.5. Future Outlook
 
6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Methodology
6.2.1. Assumptions and Parameters Evaluated
6.3. Affiliated Insights
6.3.1. Spider Web Competitive Analysis: Abzena
6.3.2. Spider Web Competitive Analysis: Cambrex
6.3.3. Spider Web Competitive Analysis: Cerbios-Pharma
6.3.4. Spider Web Competitive Analysis: Merck (SAFC)
6.3.5. Spider Web Competitive Analysis: Novasep
6.3.6. Spider Web Competitive Analysis: Pierre Fabre
6.3.7. Spider Web Competitive Analysis: Piramal Pharma Solutions
6.3.8. Spider Web Competitive Analysis: WuXi Biologics
 
7. ADC CONTRACT MANUFACTURERS: FACILITY EXPANSIONS
7.1. Chapter Overview
7.2. ADC Contract Manufacturers: Recent Facility Expansions
7.2.1. Analysis by Year of Expansion
7.2.2. Analysis by Type of Expansion
7.2.3. Analysis by Type of Service Offered
7.2.4. Analysis by Type of Service and Year of Expansion
7.2.5. Analysis by Scale of Operation
7.2.6. Analysis by Location of Facility
7.2.7. Analysis by Scale of Operation and Location of Facility
7.2.8. Analysis by Key Players and Type of Expansion
 
8. ADC CONTRACT MANUFACTURERS: RECENT PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. ADC Contract Manufacturers: List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Key Players by Number of Partnerships
8.3.4. Regional Analysis
8.3.4.1. Most Active Players
8.3.4.2. Intercontinental and Intracontinental Agreements
 
9. ADC MANUFACTURING: CAPACITY ANALYSIS
9.1. Chapter Overview
9.2. Key Assumptions and Methodology
9.3. ADC Manufacturing: Overall Installed Global Capacity
9.3.1. Distribution by Size of Manufacturers
9.3.2. Distribution by Key Players
9.3.3. Distribution by Headquarters of Manufacturers
9.3.4. Distribution by Location of Manufacturing Facilities
9.3.4.1 By Country
9.3.4.2. By Continent
 
10. ADC THERAPEUTICS: MARKET OVERVIEW
10.1. Chapter Overview
10.2. ADC Therapeutics: Clinical Pipeline
10.2.1. Distribution by Phase of Development
10.2.2. Distribution by Indication
10.2.3. Distribution by Linker Type
10.2.4. Distribution by Payload Type
10.2.5. Distribution of Technology Providers by Number of Molecules
 
10.3. ADC Therapeutics: Preclinical / Discovery Pipeline
10.3.1. Distribution of Leading Players by Number of Molecules
 
11. ADC CONJUGATION TECHNOLOGY PLATFORMS
11.1. Chapter Overview
11.2. First Generation ADC Technologies
 
11.3. Second Generation ADC Technologies
11.3.1. Cysteine and Selenocysteine Engineering
11.3.2. Unnatural Amino Acid Engineering
11.3.3. Amino-Terminal Serine Engineering
 
11.4. Third Generation ADC Technologies
11.4.1. Enzyme-Assisted Ligation Approaches
11.4.2. Glycan Remodeling Approaches
11.4.3. Ligation at Fab Nucleotide-Binding Site
11.4.4. Cysteine Rebridging
11.4.5. Avoiding or Limiting Retro-Michael Drug Deconjugation
 
11.5. Evolutionary Analysis
 
12. GEOGRAPHICAL CLINICAL TRIALS ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. ADC Therapeutics: Overall Clinical Trial Analysis
12.3.1. Analysis by Trial Registration Year
12.3.2. Geographical Analysis by Number of Clinical Trials
12.3.3. Geographical Analysis by Enrolled Patient Population
 
12.4. ADC Therapeutics: Clinical Trial Analysis by Payload Type
12.4.1. Auristatin based Molecules
12.4.1.1. Geographical Analysis by Trial Phase and Recruitment Status
12.4.1.2. Geographical Analysis by Enrolled Patient Population
12.4.1.3. Analysis by Duration of Clinical Trials
 
12.4.2. Maytansinoid based Molecules
12.4.2.1. Geographical Analysis by Trial Phase and Recruitment Status
12.4.2.2. Geographical Analysis by Enrolled Patient Population
12.4.2.3. Analysis by Duration of Clinical Trials
 
12.4.3. Calicheamicin based Molecules
12.4.3.1. Geographical Analysis by Trial Phase and Recruitment Status
12.4.3.2. Geographical Analysis by Enrolled Patient Population
12.4.3.3. Analysis by Duration of Clinical Trials
 
12.4.4. PBDs (talirine, tesirine) based Molecules
12.4.4.1. Geographical Analysis by Trial Phase and Recruitment Status
12.4.4.2. Geographical Analysis by Enrolled Patient Population
12.4.4.3. Analysis by Duration of Clinical Trials
 
12.4.5. Duocarmycin based Molecules
12.4.5.1. Geographical Analysis by Trial Phase and Recruitment Status
12.4.5.2. Geographical Analysis by Enrolled Patient Population
12.4.5.3. Analysis by Duration of Clinical Trials
 
12.4.6. DXd (exatecan Derivative) based Molecules
12.4.6.1. Geographical Analysis by Trial Phase and Recruitment Status
12.4.6.2. Geographical Analysis by Enrolled Patient Population
12.4.6.3. Analysis by Duration of Clinical Trials
 
12.4.7. Molecules having Other Types of Payloads
12.4.7.1. Geographical Analysis by Trial Phase and Recruitment Status
12.4.7.2. Geographical Analysis by Enrolled Patient Population
12.4.7.3. Analysis by Duration of Clinical Trials
 
12.5. ADC Therapeutics: Clinical Trial Analysis by Linker Type
12.5.1. VC based Molecules
12.5.1.1. Geographical Analysis by Trial Phase and Recruitment Status
12.5.1.2. Geographical Analysis by Enrolled Patient Population
12.5.1.3. Analysis by Duration of Clinical Trials
 
12.5.2. Hydrazone Linker based Molecules
12.5.2.1. Geographical Analysis by Trial Phase and Recruitment Status
12.5.2.2. Geographical Analysis by Enrolled Patient Population
12.5.2.3. Analysis by Duration of Clinical Trials
 
12.5.3. SMCC based Molecules
12.5.3.1. Geographical Analysis by Trial Phase and Recruitment Status
12.5.3.2. Geographical Analysis by Enrolled Patient Population
12.5.3.3. Analysis by Duration of Clinical Trials
 
12.5.4. VA based Molecules
12.5.4.1. Geographical Analysis by Trial Phase and Recruitment Status
12.5.4.2. Geographical Analysis by Enrolled Patient Population
12.5.4.3. Analysis by Duration of Clinical Trials
 
12.5.5. SPDB based Molecules
12.5.5.1. Geographical Analysis by Trial Phase and Recruitment Status
12.5.5.2. Geographical Analysis by Enrolled Patient Population
12.5.5.3. Analysis by Duration of Clinical Trials
 
12.5.6. Molecules having Other Types of Linkers
12.5.6.1. Geographical Analysis by Trial Phase and Recruitment Status
12.5.6.2. Geographical Analysis by Enrolled Patient Population
12.5.6.3. Analysis by Duration of Clinical Trials
 
13. ADC THERAPEUTICS: DEMAND ANALYSIS
13.1. Chapter Overview
13.2. Key Assumptions and Methodology
13.3. ADC Therapeutics: Overall Annual Demand
13.3.1. ADC Therapeutics: Annual Commercial Demand
13.3.1.1. Distribution by Payload Type
13.3.1.2. Distribution by Linker Type
13.3.1.3. Distribution by Target Cancer Type
 
13.3.2. ADC Therapeutics: Annual Clinical Demand
13.3.2.1. Distribution by Phase of Development
13.3.2.2. Distribution by Payload Type
13.3.2.3. Distribution by Linker Type
13.3.2.4. Distribution by Target Cancer Type
13.3.2.5. Distribution by Region
 
13.4. ADC Therapeutics: Demand and Supply Analysis
 
14. MARKET SIZING AND OPPORTUNITY ANALYSIS
14.1. Chapter Overview
14.2. Forecast Methodology
14.3. Overall ADC Therapeutics Market, 2018-2030
14.4. Input Data and Key Assumptions
14.5. Overall ADC Contract Manufacturing Market, 2018-2030
14.5.1. ADC Contract Manufacturing Market, 2018-2030: Distribution by Component / Process Type
14.5.2. ADC Contract Manufacturing Market, 2018-2030: Distribution by Scale of Operation
 
14.6. ADC Contract Manufacturing Market for Commercial Products, 2018-2030
14.6.1. ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Component / Process Type
14.6.2. ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Payload Type
14.6.3. ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Linker Type
14.6.4. ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Target Cancer Type
14.6.5. ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Region
 
14.7. ADC Contract Manufacturing Market for Clinical Products, 2018-2030
14.7.1. ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Component / Process Type
14.7.2. ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Payload Type
14.7.3. ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Linker Type
14.7.4. ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Target Cancer Type
14.7.5. ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Region
 
15. SWOT ANALYSIS
15.1. Chapter Overview
15.1.1. Strengths
15.1.2. Weaknesses
15.1.3. Opportunities
15.1.4. Threats
 
16. CONCLUSION
16.1. Given the Growing Pipeline of ADC Therapeutics and Associated Manufacturing Challenges, Outsourcing is Considered to be a Viable Business Strategy in this Domain
16.2. Current Market Landscape is Relatively Niche with a Limited Number of Companies Offering End-To-End Services and a Few Players Providing Services at Commercial Scale
16.3. To Keep Pace with the Growing Demand for ADC Therapeutics, Many Contract Manufacturers Have Made Investments or Entered Into Strategic Alliances to Expand Existing Capabilities
16.4. Several Clinical Trials are being Conducted to Evaluate ADC Therapeutics Worldwide, the Majority of Such Studies are Centered in the US
16.5. Owing to the Presence of Several Small Companies and Start-Ups, the Trend of Outsourcing Such Operations is Likely to Flourish in the Coming Years
16.6. The Installed Capacity is Sufficient to Meet the Current Annual Demand; However, as The Demand Rises, CMOs will be Required to Invest in Installing Incremental Capacity
 
17. INTERVIEW TRANSCRIPTS
17.1. Chapter Overview
17.2. Aldo Braca, Chief Executive Officer and Giorgio Salciarini, Technical Business Development Manager, BSP Pharmaceuticals
17.3. Anthony DeBoer, Director, Business Development, Synaffix
17.4. Christian Bailly, Director of CDMO, Pierre Fabre
17.5. Christian Rohlff, Chief Executive Officer & Founder, Oxford BioTherapeutics
17.6. Denis Angioletti, Chief Commercial Officer, Cerbios-Pharma
17.7. Jennifer L. Mitcham, Director, Business Development and Stacy McDonald, Group Product Manager, Catalent Pharma Solutions
17.8. John Burt, Chief Executive Officer, Abzena
17.9. Laurent Ducry, Head of Bioconjugates Commercial Development, Lonza
17.10. Mark Wright, Site Head, Piramal Healthcare
17.11. Sasha Koniev, Chief Executive Officer & Co-Founder, Syndivia
17.12. Anonymous, Director, Business Development, Leading CMO
17.13. Anonymous, Chief Executive Officer, Leading CMO
 
18. APPENDIX 1: TABULATED DATA
 
19. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

Figure 3.1 Components of an ADC
Figure 3.2 ADC Manufacturing Steps
Figure 4.1 ADC Contract Manufacturers: Distribution by Location of Headquarters
Figure 4.2 ADC Contract Manufacturers: Distribution by Year of Establishment
Figure 4.3 ADC Contract Manufacturers: Distribution by Company Size
Figure 4.4 ADC Contract Manufacturers: Distribution by Services Offered
Figure 4.5 ADC Contract Manufacturers: Distribution by Location of Headquarters and Services Offered
Figure 4.6 ADC Contract Manufacturers: Distribution by Location of Manufacturing Facilities
Figure 4.7 ADC Contract Manufacturers: Distribution by Scale of Operation
Figure 4.8 ADC Contract Manufacturers: Distribution based on Other Services Offered
Figure 6.1 Company Competitiveness Analysis: Methodology
Figure 6.2 Company Competitiveness Analysis: Dot-Plot Representation
Figure 6.3 Spider-Web Competitive Analysis: Abzena
Figure 6.4 Spider-Web Competitive Analysis: Cambrex
Figure 6.5 Spider-Web Competitive Analysis: Competitive Cerbios-Pharma
Figure 6.6 Spider-Web Competitive Analysis: Merck (SAFC)
Figure 6.7 Spider-Web Competitive Analysis: Novasep
Figure 6.8 Spider-Web Competitive Analysis: Pierre Fabre
Figure 6.9 Spider-Web Competitive Analysis: Piramal Pharma Solutions
Figure 6.10 Spider-Web Competitive Analysis: WuXi Biologics
Figure 7.1 ADC Contract Manufacturers: Facility Expansions, Distribution by Year, 2012-2018
Figure 7.2 ADC Contract Manufacturers: Distribution by Type of Recent Facility Expansion
Figure 7.3 ADC Contract Manufacturers: Facility Expansions, Distribution by Type of Service 
Figure 7.4 ADC Contract Manufacturers: Facility Expansions, Distribution by Type of Service and Year of Expansion
Figure 7.5 ADC Contract Manufacturers: Facility Expansions, Distribution by Scale of Operation
Figure 7.6 ADC Contract Manufacturers: Facility Expansions, Distribution by Location of Facility
Figure 7.7 ADC Contract Manufacturers: Facility Expansions, Distribution by Scale of Operation and Location of Facility
Figure 7.8 ADC Contract Manufacturers: Facility Expansions, Distribution by Key Players and Type of Expansion
Figure 8.1 ADC Contract Manufacturing: Partnerships and Collaborations, Cumulative Trend by Year, 2012-2018
Figure 8.2 ADC Contract Manufacturing: Partnerships and Collaborations, Distribution by Type of Partnership
Figure 8.3 ADC Contract Manufacturing: Partnerships and Collaborations, Most Active Players
Figure 8.4 ADC Contract Manufacturing: Partnerships and Collaborations, Regional Distribution
Figure 8.5 ADC Contract Manufacturing: Partnerships and Collaborations, Intercontinental and Intracontinental Distribution
Figure 9.1 Overall ADC Installed Manufacturing Capacity: Distribution by Size of Manufacturers
Figure 9.2 Overall ADC Installed Manufacturing Capacity: Distribution by Key Players
Figure 9.3 Overall ADC Installed Manufacturing Capacity: Distribution by Headquarters of Manufacturers
Figure 9.4 Overall ADC Installed Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (by Country)
Figure 9.5 Overall ADC Installed Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (by Continent)
Figure 10.1 ADCs Clinical Pipeline: Distribution by Phase of Development
Figure 10.2 ADCs Clinical Pipeline: Distribution by Indication
Figure 10.3 ADCs Clinical Pipeline: Distribution by Type of Linker
Figure 10.4 ADCs Clinical Pipeline: Distribution by Type of Warhead
Figure 10.5 ADCs Clinical Pipeline: Distribution by Technology Providers
Figure 10.6 ADCs Preclinical / Discovery Pipeline: Relative Distribution of Key Technology Providers
Figure 11.1 ADC Conjugation Platforms: Technological Evolution
Figure 11.2 ADC Conjugation Platforms: Technology Landscape
Figure 12.1 ADC Therapeutics: Year-wise Trend of Clinical Trials
Figure 12.2 Geographical Clinical Trial Analysis: Distribution by Number of Trials
Figure 12.3 Geographical Clinical Trial Analysis: Distribution by Enrolled Patient Population
Figure 12.4 Geographical Clinical Trial Analysis: Distribution by Payload Type
Figure 12.5 Geographical Clinical Trial Analysis (Auristatin based Molecules): Distribution by Trial Phase and Recruitment Status
Figure 12.6 Geographical Clinical Trial Analysis (Auristatin based Molecules): Distribution by Enrolled Patient Population
Figure 12.7 Geographical Clinical Trial Analysis (Maytansinoid based Molecules): Distribution by Trial Phase and Recruitment Status
Figure 12.8 Geographical Clinical Trial Analysis (Maytansinoid based Molecules): Distribution by Enrolled Patient Population 
Figure 12.9 Geographical Clinical Trial Analysis (Calicheamicin based Molecules): Distribution by Trial Phase and Recruitment Status
Figure 12.10 Geographical Clinical Trial Analysis (Calicheamicin based Molecules): Distribution by Enrolled Patient Population
Figure 12.11 Geographical Clinical Trial Analysis (PBDs based Molecules): Distribution by Trial Phase and Recruitment Status
Figure 12.12 Geographical Clinical Trial Analysis (PBDs based Molecules): Distribution by Enrolled Patient Population
Figure 12.13 Geographical Clinical Trial Analysis (Duocarmycin based Molecules): Distribution by Trial Phase and Recruitment Status
Figure 12.14 Geographical Clinical Trial Analysis (Duocarmycin based Molecules): Distribution by Enrolled Patient Population
Figure 12.15 Geographical Clinical Trial Analysis (DXd based Molecules): Distribution by Trial Phase and Recruitment Status
Figure 12.16 Geographical Clinical Trial Analysis (DXd based Molecules): Distribution by Enrolled Patient Population
Figure 12.17 Geographical Clinical Trial Analysis (Molecules having Other Types of Payloads): Distribution by Trial Phase and Recruitment Status
Figure 12.18 Geographical Clinical Trial Analysis (Molecules having Other Types of Payload): Distribution by Enrolled Patient Population
Figure 12.19 ADC Therapeutics: Geographical Clinical Trial Distribution by Linker Type
Figure 12.20 Geographical Clinical Trial Analysis (VC based Molecules): Distribution by Trial Phase and Recruitment Status
Figure 12.21 Geographical Clinical Trial Analysis (VC based Molecules): Distribution by Enrolled Patient Population
Figure 12.22 Geographical Clinical Trial Analysis (Hydrazone Linker based Molecules): Distribution by Trial Phase and Recruitment Status
Figure 12.23 Geographical Clinical Trial Analysis (Hydrazone Linker based Molecules): Distribution by Enrolled Patient Population
Figure 12.24 Geographical Clinical Trial Analysis (SMCC based Molecules): Distribution by Trial Phase and Recruitment Status
Figure 12.25 Geographical Clinical Trial Analysis (SMCC based Molecules): Distribution by Enrolled Patient Population
Figure 12.26 Geographical Clinical Trial Analysis (VA based Molecules): Distribution by Trial Phase and Recruitment Status
Figure 12.27 Geographical Clinical Trial Analysis (VA based Molecules): Distribution by Trial Phase and Recruitment Status
Figure 12.28 Geographical Clinical Trial Analysis (SPDB based Molecules): Distribution by Trial Phase and Recruitment Status
Figure 12.29 Geographical Clinical Trial Analysis (SPDB based Molecules): Distribution by Enrolled Patient Population
Figure 12.30 Geographical Clinical Trial Analysis (Molecules having Other Types of Linkers): Distribution by Trial Phase and Recruitment Status
Figure 12.31 Geographical Clinical Trial Analysis (Molecules having Other Types of Linkers): Distribution by Enrolled Patient Population
Figure 13.1  ADC Therapeutics: Overall Annual Demand, 2018-2030 (in kgs)
Figure 13.2  ADC Therapeutics: Overall Annual Demand, Distribution by Scale of Production, 2018-2030 (in kgs) 
Figure 13.3  ADC Therapeutics: Overall Annual Commercial Demand, 2018-2030 (in kgs)
Figure 13.4  Annual Commercial Demand: Distribution by Payload Type, 2018-2030 (in kgs)
Figure 13.5  Annual Commercial Demand: Distribution by Linker Type, 2018-2030 (in kgs)
Figure 13.6  Annual Commercial Demand: Distribution by Cancer Type, 2018-2030 (in kgs)
Figure 13.7  ADC Therapeutics: Overall Annual Clinical Demand, 2018-2030 (in kgs)
Figure 13.8  Annual Clinical Demand: Distribution by Phase of Development, 2018-2030 (in kgs)
Figure 13.9  Annual Clinical Demand: Distribution by Payload Type, 2018-2030 (in kgs)
Figure 13.10 Annual Clinical Demand: Distribution by Linker Type, 2018-2030 (in kgs)
Figure 13.11 Annual Clinical Demand: Distribution by Cancer Type, 2018-2030 (in kgs)
Figure 13.12 Annual Clinical Demand: Distribution by Region, 2018-2030 (in kgs)
Figure 13.13 ADC Therapeutics: Demand and Supply Scenario, 2018 - 2030
Figure 14.1 Overall ADC Therapeutics Market, 2018-2030 (USD Billion)
Figure 14.2 ADC Therapeutics: Relative Cost of Manufacturing by Component / Process Type
Figure 14.3 ADC Contract Manufacturing Market, 2018-2030: Distribution by Component / Process Type (USD Million)
Figure 14.4 ADC Contract Manufacturing Market, 2018-2030: Distribution by Scale of Operation (USD Million)
Figure 14.5 ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Component / Process Type of ADC (USD Million)
Figure 14.6 ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Payload Type (USD Million)
Figure 14.7 ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Linker Type (USD Million)
Figure 14.8 ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Target Cancer Type (USD Million)
Figure 14.9 ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Region (USD Million)
Figure 14.10 ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Component / Process Type (USD Million)
Figure 14.11 ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Payload Type (USD Million)
Figure 14.12 ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Linker Type (USD Million)
Figure 14.13 ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Target Cancer Type (USD Million)
Figure 14.14 ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Continent (USD Million)
Figure 14.15 ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Countries (USD Million)
Figure 15.1 SWOT Analysis: Harvey Ball Analysis
Figure 16.1 ADC Contract Manufacturing Market: Conservative, Base and Optimistic Scenario, 2018, 2025 and 2030 (USD Billion)

List of Tables

Table 3.1 Commonly used Cytotoxins for ADC Therapeutics
Table 3.2 OEL Bands, Safebridge Consultants
Table 4.1 ADC Contract Manufacturers: List of Service Providers
Table 4.2 ADC Contract Manufacturers: Services Offered 
Table 4.3 ADC Contract Manufacturers: Details on Manufacturing Facilities
Table 4.4 ADC Contract Manufacturers: Details on Scale of Production and Capacity
Table 4.5 ADC Contract Manufacturers: Details on Other Services Offered
Table 4.6 ADC Contract Manufacturers: List of Antibody Manufacturing Service Providers
Table 4.7 ADC Contract Manufacturers: List of HPAPI and Cytotoxic Drug Manufacturing Service Providers
Table 5.1 Abzena: Company Overview and Financial Information
Table 5.2 Abzena: ADC Related Offerings
Table 5.3 Abzena: Manufacturing Facilities Information
Table 5.4 Abzena: Recent Developments
Table 5.5 Abzena: Future Outlook
Table 5.6 Ajinomoto Althea: Company Overview and Financial Information
Table 5.7 Ajinomoto Althea: ADC Related Offerings
Table 5.8 Ajinomoto Althea: Manufacturing Facilities Information
Table 5.9 Ajinomoto Althea: Recent Developments
Table 5.10 Ajinomoto Althea: Future Outlook
Table 5.11 BSP Pharmaceuticals: Company Overview
Table 5.12 BSP Pharmaceuticals: ADC Related Offerings
Table 5.13 BSP Pharmaceuticals: Manufacturing Facilities Information
Table 5.14 BSP Pharmaceuticals: Recent Developments
Table 5.15 BSP Pharmaceuticals: Future Outlook
Table 5.16 CARBOGEN AMCIS: Company Overview and Financial Information
Table 5.17 CARBOGEN AMCIS: ADC Related Offerings
Table 5.18 CARBOGEN AMCIS: Manufacturing Facilities Information
Table 5.19 CARBOGEN AMCIS: Recent Developments
Table 5.20 Catalent Pharma Solutions: Company Overview and Financial Information
Table 5.21 Catalent Pharma Solutions: ADC Related Offerings
Table 5.22 Catalent Pharma Solutions: Manufacturing Facilities Information
Table 5.23 Catalent Pharma Solutions: Recent Developments
Table 5.24 Catalent Pharma Solutions: Future Outlook
Table 5.25 Cerbios-Pharma: Company Overview and Financial Information
Table 5.26 Cerbios-Pharma: ADC Related Offerings
Table 5.27 Cerbios-Pharma: Manufacturing Facilities Information
Table 5.28 Cerbios-Pharma: Recent Developments
Table 5.29 Cerbios-Pharma: Future Outlook
Table 5.30 Creative Biolabs: Company Overview 
Table 5.31 Creative Biolabs: ADC Related Offerings
Table 5.32 Creative Biolabs: Manufacturing Facilities Information
Table 5.33 Creative Biolabs: Recent Developments
Table 5.34 Creative Biolabs: Future Outlook
Table 5.35 Goodwin Biotechnology: Company Overview 
Table 5.36 Goodwin Biotechnology: ADC Related Offerings
Table 5.37 Goodwin Biotechnology: Manufacturing Facilities Information
Table 5.38 Goodwin Biotechnology: Recent Developments
Table 5.39 Goodwin Biotechnology: Future Outlook
Table 5.40 Levena Biopharma: Company Overview
Table 5.41 Levena Biopharma: ADC Related Offerings
Table 5.42 Levena Biopharma: Manufacturing Facilities Information
Table 5.43 Levena Biopharma: Recent Developments
Table 5.44 Levena Biopharma: Future Outlook
Table 5.45 Lonza: Company Overview and Financial Information
Table 5.46 Lonza: ADC Related Offerings
Table 5.47 Lonza: Manufacturing Facilities Information
Table 5.48 Lonza: Recent Developments
Table 5.49 Lonza: Future Outlook
Table 5.50 MabPlex: Company Overview 
Table 5.51 MabPlex: ADC Related Offerings
Table 5.52 MabPlex: Manufacturing Facilities Information
Table 5.53 MabPlex: Recent Developments
Table 5.54 MabPlex: Future Outlook
Table 5.55 Merck (SAFC): Company Overview and Financial Information
Table 5.56 Merck (SAFC): ADC Related Offerings
Table 5.57 Merck (SAFC): Manufacturing Facilities Information
Table 5.58 Merck (SAFC): Recent Developments
Table 5.59 Merck (SAFC): Future Outlook
Table 5.60 Novasep: Company Overview and Financial Information
Table 5.61 Novasep: ADC Related Offerings
Table 5.62 Novasep: Manufacturing Facilities Information
Table 5.63 Novasep: Recent Developments
Table 5.64 Novasep: Future Outlook
Table 5.65 Pierre Fabre: Company Overview and Financial Information
Table 5.66 Pierre Fabre: ADC Related Offerings
Table 5.67 Pierre Fabre: Manufacturing Facilities Information
Table 5.68 Pierre Fabre: Recent Developments
Table 5.69 Pierre Fabre: Future Outlook
Table 5.70 Piramal Pharma Solutions: Company Overview and Financial Information
Table 5.71 Piramal Pharma Solutions: ADC Related Offerings
Table 5.72 Piramal Pharma Solutions: Manufacturing Facilities Information
Table 5.73 Piramal Pharma Solutions: Recent Developments
Table 5.74 Piramal Pharma Solutions: Future Outlook
Table 5.75 Syngene: Company Overview and Financial Information
Table 5.76 Syngene: ADC Related Offerings
Table 5.77 Syngene: Information on Manufacturing Facilities
Table 5.78 Syngene: Recent Developments
Table 5.79 Syngene: Future Outlook
Table 5.80 WuXi Biologics: Company Overview and Financial Information
Table 5.81 WuXi Biologics: ADC Related Offerings
Table 5.82 WuXi Biologics: Manufacturing Facilities Information
Table 5.83 WuXi Biologics: Recent Developments
Table 5.84 WuXi Biologics: Future Outlook
Table 6.1 Company Competitiveness Analysis: Shortlisted Players
Table 6.2 Company Competitiveness Analysis: Spiderweb Parameters for Shortlisted Players
Table 7.1 ADC Contract Manufacturers: Recent Facility Expansions
Table 8.1 ADC Contract Manufacturing: Partnerships and Collaborations, 2012-2018
Table 8.2 ADC Contract Manufacturing Partnerships: Most Active Players
Table 9.1 ADC Manufacturing Installed Global Capacity: Sample Data Set 
Table 9.2 ADC Manufacturing Installed Global Capacity: Sample Data Set (Average Capacity) 
Table 9.3 ADC Manufacturing Installed Global Capacity in Grams: Total Capacity by Size of Manufacturers
Table 10.1 ADC Therapeutics: Clinical Pipeline
Table 10.2 ADC Therapeutics: Clinical Pipeline (Information on Linkers and Payloads)
Table 10.3 ADC Therapeutics: Preclinical / Discovery Pipeline
Table 11.1 Second Generation ADC Technologies: Cysteine and Selenocysteine Engineering
Table 11.2 Second Generation ADC Technologies: Unnatural Amino Acid Engineering
Table 11.3 Second Generation ADC Technologies: Amino-terminal Engineered Serine
Table 11.4 Third Generation ADC Technologies: Enzyme-Assisted Ligation Approaches
Table 11.5 Third Generation ADC Technologies: Glycan Remodeling Approaches
Table 11.6 Third Generation ADC Technologies: Enzyme-Assisted Ligation Approaches
Table 11.7 Third Generation ADC Technologies: Cysteine Rebridging
Table 11.8 Third Generation ADC Technologies: Avoiding or Limiting Retro-Michael Drug Deconjugation
Table 12.1 Geographical Clinical Trial Analysis (Auristatin Based Molecules): Duration of Trials
Table 12.2 Geographical Clinical Trial Analysis (Maytansinoid Based Molecules): Duration of Trials
Table 12.3 Geographical Clinical Trial Analysis (Calicheamicin Based Molecules): Duration of Trials
Table 12.4 Geographical Clinical Trial Analysis (PBDs Based Molecules): Duration of Trials 
Table 12.5 Geographical Clinical Trial Analysis (Duocarmycin Based Molecules): Duration of Trials
Table 12.6 Geographical Clinical Trial Analysis (DXd Based Molecules): Duration of Trials
Table 12.7 Geographical Clinical Trial Analysis (Other Types of Payload based Molecules): Duration of the Trials
Table 12.8 Geographical Clinical Trial Analysis (VC based Molecules): Duration of the Trials
Table 12.9 Geographical Clinical Trial Analysis (Hydrazone Linker Based Molecules): Duration of Trials
Table 12.10 Geographical Clinical Trial Analysis (SMCC Based Molecules): Duration of Trials
Table 12.11 Geographical Clinical Trial Analysis (VA Based Molecules): Duration of Trials
Table 12.12 Geographical Clinical Trial Analysis (SPDB Based Molecules): Duration of Trials
Table 12.13 Other Types of Linkers based ADC Therapeutics: Duration of the Trials
Table 14.1 Late Stage ADCs: Development Status
Table 14.2 ADC Therapeutics: Outsourcing Activity for Late Stage Molecules 
Table 18.1 ADC Contract Manufacturers: Distribution by Location of Headquarters
Table 18.2 ADC Contract Manufacturers: Distribution by Year of Establishment
Table 18.3 ADC Contract Manufacturers: Distribution by Company Size
Table 18.4 ADC Contract Manufacturers: Distribution by Services Offered
Table 18.5 ADC Contract Manufacturers: Distribution by Location of Headquarters and Services Offered
Table 18.6 ADC Contract Manufacturers: Distribution by Location of Manufacturing Facilities
Table 18.7 ADC Contract Manufacturers: Distribution by Scale of Operation
Table 18.8 ADC Contract Manufacturers: Distribution based on Other Services Offered
Table 18.9 ADC Contract Manufacturers: Facility Expansions, Distribution by Year, 2012-2018
Table 18.10 ADC Contract Manufacturers: Distribution by Type of Recent Facility Expansion
Table 18.11 ADC Contract Manufacturers: Facility Expansions, Distribution by Type of Service 
Table 18.12 ADC Contract Manufacturers: Facility Expansions, Distribution by Type of Service and Year of Expansion
Table 18.13 ADC Contract Manufacturers: Facility Expansions, Distribution by Scale of Operation
Table 18.14 ADC Contract Manufacturers: Facility Expansions, Distribution by Location of Facility
Table 18.15 ADC Contract Manufacturers: Facility Expansions, Distribution by Scale of Operation and Location of Facility
Table 18.16 ADC Contract Manufacturers: Facility Expansions, Distribution by Key Players and Type of Expansion
Table 18.17 ADC Contract Manufacturing: Partnerships and Collaborations, Cumulative Trend by Year, 2012-2018
Table 18.18 ADC Contract Manufacturing: Partnerships and Collaborations, Distribution by Type of Partnership
Table 18.19 ADC Contract Manufacturing: Partnerships and Collaborations, Most Active Players
Table 18.20 ADC Contract Manufacturing: Partnerships and Collaborations, Regional Distribution
Table 18.21 ADC Contract Manufacturing: Partnerships and Collaborations, Intercontinental and Intracontinental Distribution
Table 18.22 Overall ADC Installed Manufacturing Capacity: Distribution by Size of Manufacturers
Table 18.23 Overall ADC Installed Manufacturing Capacity: Distribution by Key Players
Table 18.24 Overall ADC Installed Manufacturing Capacity: Distribution by Headquarters of Manufacturers
Table 18.25 Overall ADC Installed Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (by Country)
Table 18.26 Overall ADC Installed Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (by Continent)
Table 18.27 ADCs Clinical Pipeline: Distribution by Phase of Development
Table 18.28 ADCs Clinical Pipeline: Distribution by Indication
Table 18.29 ADCs Clinical Pipeline: Distribution by Type of Linker
Table 18.30 ADCs Clinical Pipeline: Distribution by Type of Warhead
Table 18.31 ADCs Clinical Pipeline: Distribution by Technology Providers
Table 18.32 ADCs Preclinical / Discovery Pipeline: Relative Distribution of Key Technology Providers
Table 18.33 ADC Therapeutics: Year-wise Trend of Clinical Trials
Table 18.34 Geographical Clinical Trial Analysis: Distribution by Number of Trials
Table 18.35 Geographical Clinical Trial Analysis: Distribution by Enrolled Patient Population
Table 18.36 Geographical Clinical Trial Analysis: Distribution by Payload Type
Table 18.37 Geographical Clinical Trial Analysis (Auristatin based Molecules): Distribution by Trial Phase and Recruitment Status
Table 18.38 Geographical Clinical Trial Analysis (Auristatin based Molecules): Distribution by Enrolled Patient Population
Table 18.39 Geographical Clinical Trial Analysis (Maytansinoid based Molecules): Distribution by Trial Phase and Recruitment Status
Table 18.40 Geographical Clinical Trial Analysis (Maytansinoid based Molecules): Distribution by Enrolled Patient Population 
Table 18.41 Geographical Clinical Trial Analysis (Calicheamicin based Molecules): Distribution by Trial Phase and Recruitment Status
Table 18.42 Geographical Clinical Trial Analysis (Calicheamicin based Molecules): Distribution by Enrolled Patient Population
Table 18.43 Geographical Clinical Trial Analysis (PBDs based Molecules): Distribution by Trial Phase and Recruitment Status
Table 18.44 Geographical Clinical Trial Analysis (PBDs based Molecules): Distribution by Enrolled Patient Population
Table 18.45 Geographical Clinical Trial Analysis (Duocarmycin based Molecules): Distribution by Trial Phase and Recruitment Status
Table 18.46 Geographical Clinical Trial Analysis (Duocarmycin based Molecules): Distribution by Enrolled Patient Population
Table 18.47 Geographical Clinical Trial Analysis (DXd based Molecules): Distribution by Trial Phase and Recruitment Status
Table 18.48 Geographical Clinical Trial Analysis (DXd based Molecules): Distribution by Enrolled Patient Population
Table 18.49 Geographical Clinical Trial Analysis (Molecules having Other Types of Payloads): Distribution by Trial Phase and Recruitment Status
Table 18.50 Geographical Clinical Trial Analysis (Molecules having Other Types of Payload): Distribution by Enrolled Patient Population
Table 18.51 ADC Therapeutics: Geographical Clinical Trial Distribution by Linker Type
Table 18.52 Geographical Clinical Trial Analysis (VC based Molecules): Distribution by Trial Phase and Recruitment Status
Table 18.53 Geographical Clinical Trial Analysis (VC based Molecules): Distribution by Enrolled Patient Population
Table 18.54 Geographical Clinical Trial Analysis (Hydrazone Linker based Molecules): Distribution by Trial Phase and Recruitment Status
Table 18.55 Geographical Clinical Trial Analysis (Hydrazone Linker based Molecules): Distribution by Enrolled Patient Population
Table 18.56 Geographical Clinical Trial Analysis (SMCC based Molecules): Distribution by Trial Phase and Recruitment Status
Table 18.57 Geographical Clinical Trial Analysis (SMCC based Molecules): Distribution by Enrolled Patient Population
Table 18.58 Geographical Clinical Trial Analysis (VA based Molecules): Distribution by Trial Phase and Recruitment Status
Table 18.59 Geographical Clinical Trial Analysis (VA based Molecules): Distribution by Trial Phase and Recruitment Status
Table 18.60 Geographical Clinical Trial Analysis (SPDB based Molecules): Distribution by Trial Phase and Recruitment Status
Table 18.61 Geographical Clinical Trial Analysis (SPDB based Molecules): Distribution by Enrolled Patient Population
Table 18.62 Geographical Clinical Trial Analysis (Molecules having Other Types of Linkers): Distribution by Trial Phase and Recruitment Status
Table 18.63 Geographical Clinical Trial Analysis (Molecules having Other Types of Linkers): Distribution by Enrolled Patient Population
Table 18.64 ADC Therapeutics: Overall Annual Demand, 2018-2030 (in kgs)
Table 18.65 ADC Therapeutics: Overall Annual Demand, Distribution by Scale of Operation, 2018-2030 (in kgs) 
Table 18.66 ADC Therapeutics: Overall Annual Commercial Demand, 2018-2030 (in kgs)
Table 18.67 Annual Commercial Demand: Distribution by Payload Type, 2018-2030 (in kgs)
Table 18.68 Annual Commercial Demand: Distribution by Linker Type, 2018-2030 (in kgs)
Table 18.69 Annual Commercial Demand: Distribution by Target Cancer Type, 2018-2030 (in kgs)
Table 18.70 ADC Therapeutics: Overall Annual Clinical Demand, 2018-2030 (in kgs)
Table 18.71 Annual Clinical Demand: Distribution by Phase of Development, 2018-2030 (in kgs)
Table 18.72 Annual Clinical Demand: Distribution by Payload Type, 2018-2030 (in kgs)
Table 18.73 Annual Clinical Demand: Distribution by Linker Type, 2018-2030 (in kgs)
Table 18.74 Annual Clinical Demand: Distribution by Target Cancer Type, 2018-2030 (in kgs)
Table 18.75 Annual Clinical Demand: Distribution by Region, 2018-2030 (in kgs)
Table 18.76 Overall ADC Therapeutics Market: Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 18.77 ADC Therapeutics: Relative Cost of Manufacturing by Component / Process Type
Table 18.78 ADC Contract Manufacturing Market, 2018-2030: Distribution by Component / Process Type (USD Million), Conservative, Base and Optimistic Scenarios
Table 18.79 ADC Contract Manufacturing Market, 2018-2030: Distribution by Scale of Operation (USD Million), Conservative, Base and Optimistic Scenarios
Table 18.80 ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Component / Process Type (USD Million), Conservative, Base and Optimistic Scenarios
Table 18.81 ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Payload Type (USD Million), Conservative, Base and Optimistic Scenarios
Table 18.82 ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Linker Type (USD Million), Conservative, Base and Optimistic Scenarios
Table 18.83 ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Target Cancer Type (USD Million), Conservative, Base and Optimistic Scenarios
Table 18.84 ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Region (USD Million), Conservative, Base and Optimistic Scenarios
Table 18.85 ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Components of ADC (USD Million), Conservative, Base and Optimistic Scenarios
Table 18.86 ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Payload Type (USD Million), Conservative, Base and Optimistic Scenarios
Table 18.87 ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Linker Type (USD Million), Conservative, Base and Optimistic Scenarios
Table 18.88 ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Target Cancer Type (USD Million), Conservative, Base and Optimistic Scenarios
Table 18.89 ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Region (USD Million), Conservative, Base and Optimistic Scenarios
Table 18.90 ADC Contract Manufacturing Market: Conservative, Base and Optimistic Scenario, 2018, 2025 and 2030 (USD Billion)

Listed Companies

The following companies and organizations have been mentioned in the report. 

  1. 3P Biopharmaceuticals
  2. AB Sciex
  3. AbbVie
  4. AbGenomics
  5. ABL Bio 
  6. Abzena
  7. ACES Pharma
  8. Adar Biotech
  9. ADC Biotechnology
  10. ADC Therapeutics 
  11. Advanced BioScience Laboratories 
  12. Aesica Pharmaceuticals 
  13. Affinity Life Sciences
  14. Agensys
  15. Agno Pharma
  16. Ajinomoto Althea
  17. Alcami
  18. Aldevron
  19. Alkermes 
  20. Allozyne 
  21. Almac 
  22. Alpha Cancer Technologies 
  23. Alphora Research
  24. Alteogen
  25. Amatsigroup 
  26. Ambrx 
  27. Amgen
  28. AMPAC Fine Chemicals
  29. AMRI
  30. Angiex
  31. Anogen
  32. APO-T
  33. Aptuit
  34. AqueaTether Therapeutics
  35. Arabio
  36. Arch Pharmalabs
  37. Asana BioSciences
  38. Ash Stevens 
  39. Aspyrian Therapeutics 
  40. Astellas Pharma
  41. AstraZeneca
  42. Asymchem 
  43. AURA Biotechnologies 
  44. AutekBio
  45. Avanthera 
  46. Avid Bioservices
  47. Batavia Biosciences
  48. Baxter BioPharma Solutions
  49. Bayer HealthCare
  50. BerGenBio 
  51. Bharat Serums and Vaccines
  52. BIBITEC
  53. BINEX
  54. BioAgilytix
  55. BioConnection
  56. Biomatik
  57. BioMed Valley Discoveries
  58. Biosynergy
  59. Bio-Synthesis
  60. BioTechLogic 
  61. BioTechnique
  62. Biotechpharma
  63. Biotecnol 
  64. Biotest
  65. BioVectra
  66. Biovian
  67. BlinkBio
  68. Bliss Biopharmaceutical
  69. Boehringer Ingelheim BioXcellence 
  70. Bristol-Myers Squibb
  71. Bryllan
  72. BSP Pharmaceuticals
  73. Cambrex
  74. Cambridge Major Laboratories
  75. Capsugel
  76. CARBOGEN AMCIS
  77. Catalent Pharma Solutions
  78. Cedarburg Pharmaceuticals 
  79. Celgene 
  80. Cell Culture Company
  81. Cell Essentials
  82. Cellerant Therapeutics
  83. CellMosaic 
  84. Celltrion
  85. Celon Laboratories
  86. Celonic
  87. Centrose 
  88. Cerbios-Pharma
  89. Charles River Laboratories
  90. ChemCon
  91. ChemPartner
  92. ChemSun Pharmaceutical
  93. Chiome Bioscience
  94. Chugai Pharmaceutical
  95. CinnaGen 
  96. CMC Biologics
  97. Cobra Biologics
  98. Coldstream Laboratories 
  99. Compugen
  100. Concortis Biotherapeutics
  101. Cook Pharmica
  102. CordenPharma
  103. Creative Biolabs
  104. Crystal Pharma 
  105. Custom Pharma Services 
  106. CytomX Therapeutics
  107. Cytovance Biologics
  108. Daiichi Sankyo
  109. Dalton Pharma Services
  110. Debiopharm
  111. DM Bio
  112. Dorizoe Lifesciences
  113. Dottikon Exclusive Synthesis
  114. DSM Pharmaceuticals
  115. EirGen Pharma 
  116. EirGenix
  117. Eli Lilly
  118. Emergent BioSolutions
  119. Esperance Pharmaceuticals
  120. ETH Zurich 
  121. EuBiologics
  122. Evonik  
  123. Excella 
  124. Farmabios
  125. FineTech Pharmaceuticals 
  126. Formation Biologics
  127. Formex
  128. Formosa Laboratories 
  129. For-Robin
  130. Fortis Therapeutics
  131. FOSUN Pharma
  132. FUJIFILM Diosynth Biotechnologies
  133. Fusion Antibodies
  134. Gala Biotech
  135. GE Healthcare
  136. GEA Pharma Systems 
  137. Genentech 
  138. Genmab
  139. Genzyme 
  140. Glenmark Pharmaceuticals
  141. Glycotope Biotechnology
  142. Glythera
  143. Goodwin Biotechnology
  144. GP Pharm
  145. Grand River Aseptic Manufacturing
  146. Green Cross 
  147. Groningen Research Institute of Pharmacy
  148. GSK
  149. GTP Technology
  150. HALIX 
  151. Halozyme
  152. Hangzhou DAC Biotech 
  153. Haupt Pharma 
  154. Heidelberg Pharma
  155. Helsinn Advanced Synthesis
  156. Heraeus Deutschland 
  157. Hetero 
  158. Hong Kong Institute of Biotechnology
  159. ICROM
  160. Idifarma 
  161. IDT Australia 
  162. IDT Biologika
  163. Igenica Biotherapeutics
  164. ImmunoGen
  165. Immunomedics 
  166. Indena
  167. Innate Pharma 
  168. Inno Biologics 
  169. Innovation Center for Immune Therapy,  Tsinghua University
  170. Intas Pharmaceuticals
  171. Integrity Bio
  172. Intellect Neurosciences
  173. IRIX Pharmaceuticals 
  174. JHL Biotech
  175. Johns Hopkins University
  176. Johnson Matthey 
  177. Kamat Pharmatech
  178. KBI Biopharma
  179. Kemwell Biopharma
  180. Kyongbo Pharmaceutical 
  181. Kyowa Hakko Kirin
  182. Labochim 
  183. LAMPIRE Biological Laboratories
  184. LegoChem Biosciences
  185. Leica Biosystems
  186. Levena Biopharma
  187. LFB Biomanufacturing
  188. LinXis 
  189. Lonza
  190. MAB Discovery
  191. MabPlex
  192. MabVax Therapeutics
  193. MacroGenics 
  194. Maine Biotechnology Services
  195. MassBiologics
  196. Medichem
  197. MedImmune
  198. Meditope Biosciences
  199. Medix Biochemica
  200. Menarini Group
  201. Merck (SAFC)
  202. Meridian Life Science
  203. Merrimack Pharmaceuticals
  204. Mersana Therapeutics 
  205. Metrics Contract Services 
  206. Millennium Pharmaceuticals
  207. MINAKEM High Potent 
  208. Mitsubishi Tanabe Pharma 
  209. Molecular and Cellular Therapeutics, University of Minnesota
  210. Morphotek
  211. MuseChem
  212. Mycenax Biotech
  213. NanoValent Pharmaceuticals
  214. National Cancer Institute
  215. National Research Council Canada 
  216. NBE Therapeutics
  217. NerPharma 
  218. Nitto Avecia Pharma Services
  219. Nordic Nanovector 
  220. Laboratorios Normon
  221. Nova Laboratories
  222. Novartis
  223. Novasep
  224. OBI Pharma
  225. OctoPlus
  226. Olon
  227. OmniChem
  228. Oncotec Pharma Produktion
  229. Hospira One2One 
  230. OsoBio
  231. Oxford BioTherapeutics
  232. Panacea Biotec
  233. Paragon Bioservices
  234. Particle Sciences
  235. Patheon
  236. Penn Pharma
  237. Pfanstiehl
  238. Pfizer
  239. Pharmaceutics International 
  240. PharmaMar
  241. Pharmatek
  242. Pharmedartis
  243. Philochem
  244. Philogen
  245. Pierre Fabre
  246. Piramal Pharma Solutions
  247. Polymun Scientific
  248. PrasFarma
  249. Praxis Pharmaceutical
  250. Precision Antibody
  251. PREMAS Biotech
  252. ProBioGen
  253. Procos
  254. ProJect Pharmaceutics
  255. ProMab Biotechnologies
  256. PX'Therapeutics
  257. Quotient Sciences 
  258. Recipharm
  259. Redwood Bioscience
  260. Regeneron Pharmaceuticals
  261. Regis Technologies
  262. Reliance Life Sciences
  263. RemeGen
  264. Rentschler Biopharma
  265. Research Corporation Technologies
  266. Richter-Helm BioLogics
  267. Roche 
  268. Rottendorf Pharma
  269. Saltigo 
  270. Samsung Medical Center
  271. Sandoz 
  272. Sanofi
  273. Sartorius Stedim Biotech
  274. ScinoPharm
  275. Seasun Biomaterials
  276. Seattle Genetics 
  277. Shenogen
  278. Siegfried
  279. Sorrento Therapeutics 
  280. Spirogen 
  281. STA Pharmaceutical
  282. Stason Pharmaceuticals
  283. Stemcentrx
  284. Sutro Biopharma 
  285. Symbiosis Pharmaceutical Services
  286. Symphogen
  287. Synaffix
  288. Syndivia
  289. Syngene
  290. Syntagon
  291. Synthon
  292. Synthorx
  293. Takara Bio
  294. Takeda Oncology
  295. TAPI 
  296. TBD-Biodiscovery
  297. Telix Pharmaceuticals
  298. The Chemistry Research Solution
  299. The Scripps Research Institute
  300. Theranyx 
  301. Therapure Biopharma 
  302. Thermo Fisher Scientific
  303. Toyobo Biologics 
  304. Transporin
  305. TranXenoGen
  306. Triphase Accelerator
  307. Tube Pharma 
  308. Uman Pharma
  309. University of Bonn 
  310. University of California
  311. University of Georgia
  312. UPM Pharmaceuticals
  313. Uquifa
  314. Vaccinex
  315. Vetter Pharma 
  316. Vista Biologicals
  317. Visterra
  318. VUAB Pharma
  319. Waisman Biomanufacturing
  320. Weill Cornell Medicine
  321. Wolfe Laboratories
  322. WuXi Biologics
  323. Xintela
  324. Yale School of Medicine
  325. Zymeworks
     

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 3,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com